This article covers the existing view about the overlapping pathogenetic mechanisms of thrombosis in systemic lupus erythematosus and antiphospholipid syndrome, the relevance of these researches during the COVID-19 pandemic, as well as the leads for antithrombotic and anti inflammatory therapy.In April 2023, a well-known professional and cardiologist, a number one expert within the study of pathogenetic mechanisms, analysis and treatment of arterial hypertension, Vice-President associated with Russian Medical Society for Arterial Hypertension, Professor Valery Ivanovich Podzolkov celebrated his anniversary.The article discusses the phases of development and development of ultrasound diagnostics, including those with contrast enhancement. The key forms of contrast agents and their method of activity tend to be presented. Samples of making use of contrast-enhanced ultrasound in several industries of medication are given. The leads associated with the strategy and its own place in clinical rehearse tend to be discussed.Screening for atrial fibrillation (AF) features drawn significant attention recently. Of special-interest tend to be patients with cardiac implantable electronic devices (CIEDs) that enable for tracking attacks of atrial arrhythmias of varied durations, including asymptomatic people, in which particular case these are generally known as subclinical atrial fibrillation (SCAF). The readily available data declare that the possibility of thromboembolic occasions varies between patients with SCAF and clinically overt AF. As of today, the question Stereotactic biopsy regarding anticoagulant therapy in patients with SCAF stays unresolved. The article provides a summary of past and ongoing scientific studies about this issue, along with present recommendations on anticoagulant use within patients with SCAF and CIEDs.The article defines the key types of evaluation of physiological importance of coronary artery stenoses, their particular use within medical practice and future perspectives. New diagnostic practices that are click here presently under analysis tend to be discussed.Transthyretin amyloidosis (ATTR-amyloidosis) is a systemic condition associated with extracellular deposition within the areas and body organs of amyloid fibrils, transthyretin-containing insoluble protein-polysaccharide buildings. The alteration in transthyretin conformation, ultimately causing its destabilization and amyloidogenicity, can be acquired (wild type, ATTRwt) and hereditary due to mutations into the TTR gene (variant, ATTRv) [1, 2]. Hereditary ATTR-amyloidosis features an earlier onset and greater phenotypic diversity. Age the manifestation, the prevalent phenotype, as well as the prognosis are often determined by the genetic variation. To date, more than 140 variants in the TTR gene being identified; but, most of them tend to be described in single customers and don’t have clear proof of pathogenicity. The customers of a brand new pathogenetic treatment of ATTR-amyloidosis [3], especially efficient in the early stages associated with the illness, advances the relevance of timely diagnosis, that will be difficult due to doctors’ not enough understanding. This short article provides a clinical situation of ATTRv-amyloidosis related to a rare pathogenic variation into the TTR gene and a newly described epidermis symptom. This short article is a literature review.Diagnosis and treatment of myocarditis can be challenging, including deciding indications for heart transplantation. We provide a 6-year medical history of a 54 yrs old client with severe morphologically confirmed viral-negative lymphocytic myocarditis and systemic manifestations (onset of hemorrhagic vasculitis) coupled with moderate coronary atherosclerosis, which regressed based on duplicated coronary angiography. For five years, the individual got immunosuppressive treatment with methylprednisolone and azathioprine with a substantial enhancement. Duplicated relapses of atrial fibrillation required correction of basic treatment and plasmapheresis. The illness had been difficult by thyrotoxicosis and multi-organ dysfunction; the autopsy revealed persistent myocarditis task. The myocarditis is a chronic condition and requires overview of the treatment method at each stage. To assess the anti inflammatory effectiveness of Regasthym Gastro (alpha-glutamyl-tryptophan) into the remedy for customers with persistent atrophic gastritis according to endoscopic and morphometric scientific studies. in exacerbation 43 clients took Regasthym Gastro, 37 customers – placebo. The conclusions associated with gastroscopy had been organized by means of a standardised scale, which included an assessment of requirements in things (from 0 to 3) thickness of folds, hyperemia, edema of this gastric mucosa, signs and symptoms of atrophy, metaplasia; the severity of the erosive process. The sum of points relating to all requirements ended up being made use of to assess the characteristics associated with the inflammatory procedure positive dynamics; lack of characteristics; the pathological procedure is advancing. The results for the endoscopic assessment had been comparvaluation for the link between gastroscopy and morphometry. You are able to recommend the addition of the drug within the complex therapy of chronic gastritis to boost the effectiveness and reduce the potential risks of development of inflammation.Regasthym Gastro plays a role in a substantial decrease in Mutation-specific pathology the seriousness of the inflammatory process according into the evaluation associated with the link between gastroscopy and morphometry. It is possible to suggest the inclusion of this drug when you look at the complex therapy of persistent gastritis to increase the effectiveness and minimize the potential risks of progression of irritation.